134 related articles for article (PubMed ID: 26982320)
21. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
[TBL] [Abstract][Full Text] [Related]
22. Preformulation studies of novel 5'-O-carbonates of lamivudine with biological activity: solubility and stability assays.
Gualdesi MS; Ravetti S; Raviolo MA; Briñón MC
Drug Dev Ind Pharm; 2014 Sep; 40(9):1246-52. PubMed ID: 23855736
[TBL] [Abstract][Full Text] [Related]
23. Strategies to improve the solubility and stability of stilbene antioxidants: a comparative study between cyclodextrins and bile acids.
Silva F; Figueiras A; Gallardo E; Nerín C; Domingues FC
Food Chem; 2014 Feb; 145():115-25. PubMed ID: 24128457
[TBL] [Abstract][Full Text] [Related]
24. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
25. Piperlongumine: the amazing amide alkaloid from Piper in the treatment of breast cancer.
Mitra S; Biswas P; Bandyopadhyay A; Gadekar VS; Gopalakrishnan AV; Kumar M; Radha ; Nandy S
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):2637-2650. PubMed ID: 37955690
[TBL] [Abstract][Full Text] [Related]
26. Preformulation study of pelrinone hydrochloride.
Hajdu J; Adams G; Lee HK
J Pharm Sci; 1988 Nov; 77(11):921-5. PubMed ID: 3225750
[TBL] [Abstract][Full Text] [Related]
27. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity.
Han LC; Stanley PA; Wood PJ; Sharma P; Kuruppu AI; Bradshaw TD; Moses JE
Org Biomol Chem; 2016 Aug; 14(31):7585-93. PubMed ID: 27443386
[TBL] [Abstract][Full Text] [Related]
28. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells.
Yao Y; Sun Y; Shi M; Xia D; Zhao K; Zeng L; Yao R; Zhang Y; Li Z; Niu M; Xu K
Oncotarget; 2016 Nov; 7(45):73497-73508. PubMed ID: 27634873
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol.
Xu X; Fang X; Wang J; Zhu H
Bioorg Med Chem Lett; 2017 Mar; 27(5):1325-1328. PubMed ID: 28159415
[TBL] [Abstract][Full Text] [Related]
30. Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions.
Jiang S; Wang F; Zhu S; Zhang X; Guo Z; Li R; Xu Q
Int J Pharm; 2013 May; 448(2):390-3. PubMed ID: 23541985
[TBL] [Abstract][Full Text] [Related]
31. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
[TBL] [Abstract][Full Text] [Related]
32. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A(2) receptor antagonist.
Iwashita M; Oka N; Ohkubo S; Saito M; Nakahata N
Eur J Pharmacol; 2007 Sep; 570(1-3):38-42. PubMed ID: 17618620
[TBL] [Abstract][Full Text] [Related]
33. Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives.
Dollo G; Le Corre P; Chollet M; Chevanne F; Bertault M; Burgot JL; Le Verge R
J Pharm Sci; 1999 Sep; 88(9):889-95. PubMed ID: 10479350
[TBL] [Abstract][Full Text] [Related]
34. Solubilization and preformulation of carbendazim.
Ni N; Sanghvi T; Yalkowsky S
Int J Pharm; 2002 Sep; 244(1-2):99-104. PubMed ID: 12204569
[TBL] [Abstract][Full Text] [Related]
35. Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells.
Ryu J; Kim MJ; Kim TO; Huh TL; Lee SE
Nat Prod Res; 2014; 28(22):2040-3. PubMed ID: 24853732
[TBL] [Abstract][Full Text] [Related]
36. Salt formation improved the properties of a candidate drug during early formulation development.
Sigfridsson K; Ahlqvist M; Lindsjö M; Paulsson S
Eur J Pharm Sci; 2018 Jul; 120():162-171. PubMed ID: 29730322
[TBL] [Abstract][Full Text] [Related]
37. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: stability, solubility, lipophilicity and ionization.
See E; Zhang W; Liu J; Svirskis D; Baguley BC; Shaw JP; Wang G; Wu Z
Int J Pharm; 2014 Oct; 473(1-2):528-35. PubMed ID: 25079434
[TBL] [Abstract][Full Text] [Related]
38. Spectroscopic investigation of the anticancer alkaloid piperlongumine binding to human serum albumin from the viewpoint of drug delivery.
Liu Y; Li QY; Wang YP; Liu YM; Liu B; Liu MM; Liu BM
Luminescence; 2018 Mar; 33(2):305-311. PubMed ID: 29044986
[TBL] [Abstract][Full Text] [Related]
39. NP-647, a novel TRH analogue: investigating physicochemical parameters critical for its oral and parenteral delivery.
Khomane K; Kumar L; Meena CL; Jain R; Bansal A
Int J Pharm; 2011 Mar; 406(1-2):21-30. PubMed ID: 21185925
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure and physicochemical properties of crystalline form of 2'-O-{3-[(7-chloro-4-quinolinyl)amino]propyl}-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A.
Filić D; Starčević K; Pešić D; Jurmanović S; Meenan E; Spezzaferri A; Đilović I; Prugovečki B
J Pharm Sci; 2011 Jul; 100(7):2586-98. PubMed ID: 21394721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
